Pregnancy registries

INC Research's experience developing, implementing, and managing pregnancy registries is unsurpassed. We currently manage more pregnancy registries than any other CRO.

Below is contact information and links to our active pregnancy registry web sites for use by both patients and physicians.

Active Registries

Adenovirus Vaccine Pregnancy Registry

This is a prospective, observational, exposure-registration and follow-up study of pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral and their live born offspring through the first year of life. Enrollment may be initiated by pregnant patients or health care providers of pregnant patients who received Adenovirus Type 4 and Type 7 Vaccine, Live, Oral while pregnant or who conceived within 6 weeks of vaccine administration. Please contact the Adenovirus Vaccine Pregnancy Registry via

Phone: 1.866.790.4549
Fax: 1.866.586.8406
Email: adenovirus@incresearch.com

Please reference http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM247515.pdffor package insert/prescribing information.

 

Antiretroviral Pregnancy Registry

http://www.apregistry.com

 

Betaseron® Pregnancy Registry

The Betaseron Pregnancy Registry, sponsored by Bayer HealthCare, is closed to enrollment and follow up.


Email: pregnancyregistries@incresearch.com

 

Cymbalta® Pregnancy Registry

http://www.cymbaltapregnancyregistry.com

Pregnant patients who have taken Cymbalta® at any time during pregnancy and their health care providers may contact The Cymbalta® Pregnancy Registry via:

Phone: 1-866-814-6975

Email: pregnancyregistries@incresearch.com

 

Exenatide Pregnancy Registry

http://www.exenatidepregnancyregistry.com

Pregnant patients or health care providers of pregnant patients exposed to exenatide (BYETTA® injection or other formulations of exenatide) and/or one or more other non-insulin antidiabetic medications at the time of conception (i.e., on or after the first day of the last menstrual period) may contact the registry at:

Phone: 800-633-9081

Email: pregnancyregistries@incresearch.com

 

A Global Gleevec®/Glivec® & Tasigna® Pregnancy Exposure Registry

This is a voluntary, international, primarily prospective, observational, exposure-registration and follow-up study of women receiving Gleevec/Glivec or Tasigna during pregnancy or within six months prior to pregnancy.

Phone: 877-513-6684
Fax: 877-513-6682
Email: Novartis.20679@kendle.com

 

Ribavirin Pregnancy Registry

http://ribavirinpregnancyregistry.com

Phone: 800-593-2214
Fax: 800-800-1052
Email:  pregnancyregistries@incresearch.com

 

The Savella Pregnancy Registry

http://www.savellapregnancyregistry.com

Pregnant patients exposed to Savella during pregnancy

Phone: 1- 877.643.3010
Fax : 1.800.800.1052
Email:  pregnancyregistries@incresearch.com

 

Sumatriptan/Naratriptan/Treximet Pregnancy Registry

The Sumatriptan/Naratriptan/Treximet Pregnancy Registry, sponsored by GlaxoSmithKline, is closed to enrollment and follow up. To access the most recent registry report, please click on the link below, which will take you to the GlaxoSmithKline Sumatriptan/Naratriptan/Treximet Pregnancy Registry web page.

http://pregnancyregistry.gsk.com/sumatriptan.html

 

UCB AED Pregnancy Registry

As of 01-Jan-2013, the US-based UCB AED (Antiepileptic drug(s)) Pregnancy Registry) is no longer accepting new registrations. The registry is presently continuing follow-up activities for previously registered participants who had exposure to Keppra® or Keppra XR® prior to conception and during their pregnancy.

If you would like to contribute information and enroll in a different AED registry, please contact The North American Antiepileptic Drug Pregnancy Registry by dialing 1-888-233-2334 or visiting their website at http://www.aedpregnancyregistry.org/.

For prescribing or reference information for Keppra® or Keppra XR®, please go to www.keppra.com.

For UCB AED Pregnancy Registry follow-up questions:

Phone:  1-888-537-7734 (1-888-KEP-PREG)

Email:  pregnancyregistries@incresearch.com